Background: To evaluate the correlation between COX-2 overexpression and clinicopathological features of gastric cancer, thus providing theoretical basis for anti-COX-2 targeted therapy. Methods: The literature about COX-2 expression and gastric cancer was searched in PubMed, Wangfang, VIP, CNKI from the inception to September 2019, with “gastric cancer”, “COX-2”, “cyclooxygenase” as keywords. Stata 15.0 was used to analyze. Age, gender, differentiation, infiltration depth, lymph node metastasis, tumor size, TNM staging were analyzed by OR (95% CI). Results: Nine studies involving 1,289 patients with gastric cancer were identified, among which 878 cases existed COX-2 overexpression. COX-2 overexpression was related to the infiltration depth (OR=1.76; 95% CI: 1.01–1.306; P<0.01) and lymph node metastasis (OR=3.08; 95% CI: 1.64–5.79; P<0.01). While, it was not related to age, gender, differentiation and tumor size. Conclusions: COX-2 overexpression is valuable in predicting infiltration depth and lymph node metastasis, and could be a predictor of poor prognosis in gastric cancer. COX-2-targeted therapy can be considered as one of the comprehensive treatments for gastric cancer.
Ulcerative colitis (UC) is characterized by intertwined defects in the epithelial barrier, microbiota composition, and immune signaling, which collectively
30 December 2025 in Immunity, Inflammation and Disease
Background: Colorectal cancer (CRC) is a leading cause of cancer‐related mortality, which necessitates the exploration of novel therapeutic targets. Objective: This study aims to investigate the effects of Prolyl 4‐hydroxylase subunit alpha‐1 (P4HA1) inhibition on CRC tumor growth, metastasis, and tumor‐associated macrophage (TAM) infiltration. Methods: The association between P4HA1 expression and CRC progression as well as tumor immune infiltration was analyzed. In vitro experiments were performed to evaluate the effect of targeting P4HA1 on CRC cell proliferation and migration. The secretion of CCL2, CCL4, and CCL7 and recruitment of TAMs were detected after P4HA1 knockdown. Mechanistic studies were conducted to explore the interaction between P4HA1 and P4HA2 and its regulation on the PI3K‐AKT signaling pathway. In vivo experiments were also carried out to verify the effect of P4HA1 knockdown on CRC tumor growth, metastasis, and TAM infiltration polarization. Results: P4HA1 expression was found to be associated with CRC progression and tumor immune infiltration. Targeting P4HA1 significantly suppressed CRC cell proliferation and migration in vitro. Moreover, P4HA1 knockdown reduced the secretion of CCL2, CCL4, CCL7 and the recruitment of TAMs. Mechanistically, P4HA1 interacted with P4HA2, thereby disrupting the PI3K‐AKT signaling pathway which is crucial for CRC progression and TAMs recruitment. In vivo experiments confirmed that P4HA1 knockdown inhibited CRC tumor growth, metastasis, and TAM infiltration polarization. Conclusion: Our findings elucidate the importance of the P4HA1‐P4HA2‐PI3K‐AKT axis in CRC and identify P4HA1 as a promising therapeutic target to impede CRC growth and metastasis while altering the tumor immune landscape. This research provides a foundation for further investigations into P4HA1‐targeted therapies, which may improve clinical outcomes for patients with CRC.
Background. Hepatocellular carcinoma (HCC) is the sixth most common tumor worldwide. Additionally, deletion of RAPGEF2 plays a critical role in CNV and related to tumor immune microenvironment, whereas the prognostic potential of RAPGEF2 in HCC patient needs to be explored. Methods. We looked for prognostic potential genes in HCC using a variety of R programs. Then, using the LASSO Cox regression, we thoroughly evaluated and integrated the RAPGEF2-related genes from TCGA database. Meanwhile, utilizing TCGA and ICGA databases, the link between RAPGEF2 and immunotherapy response in HCC was studied. In vivo, the effect of RAPGEF2 on tumor development and the capacity of natural killer (NK) cells to recruit were confirmed. To ascertain the connection between RAPGEF2-related genes and the prognosis of HCC, a prognostic model was created and validated. Result. We demonstrated RAPGEF2 has a differential expression, and patients with deletion of RAPGEF2 gene get shorter survival in HCC. Additionally, the tissues without RAPGEF2 have a weaker ability to recruit the NK cells and response to immunotherapy. After that, we scoured the database for eight RAPGEF2-related genes linked with a better prognosis in HCC patients. Additionally, silencing RAPGEF2 accelerated tumor development in the HCC mouse model and decreased CD56+ NK cell recruitment in HCC tissues. TCGA database was used to classify patients into low- and high-risk categories based on the expression of related genes. Patients in the low-risk group had a significantly greater overall survival than those in the high-risk group ( ). Meanwhile, the low-risk group demonstrated connections with the NK cell and immunotherapy response. Finally, the prognostic nomogram showed a high sensitivity and specificity for predicting the survival of HCC patients at 1, 2, and 3 years. Conclusion. The prognostic model based on RAPGEF2 and RAPGEF2-related genes showed an excellent predictive performance in terms of prognosis and immunotherapy response in HCC, therefore establishing a unique prognostic model for clinical assessment of HCC patients.